A treatment to reduce blood pressure between patients with type 2 diabetes is associated with a lower risk of cardiovascular disease (ECV) and heart disease and mortality improvement, according to a study published this Tuesday in the magazine 'Jama'.
By 2030, it is estimated that there will be at least 400 million people with type 2 diabetes mellitus worldwide.Type 2 diabetes is associated with a significantly greater risk of problems such as heart attack and stroke.
Blood pressure (PA) levels are on average higher between people with diabetes and the increase in PA is a well -established risk factor for people with diabetes.The reduction of blood pressure in these patients is a controversy area currently, with a special debate around which therapy should be offered and the objectives to be achieved, according to the information support information.
Kazem Rahimi, of the George Institute for Global Health of the University of Oxford, in the United Kingdom, and its colleagues conducted a large -scale meta -analysis of random controlled tests of antihypertensive treatments including patients with diabetes, published between January 1966 andOctober 2014.
A search in the medical literature identified 40 essays that were considered low bias (100,354 participants) and were included in the research to examine associations between antihypertensive treatment and vascular disease in type 2 diabetes.
The researchers found that each 10 mm HG decrease in systolic blood pressure was associated with a lower risk of mortality, cardiovascular events, coronary heart disease, stroke, albuminuria (presence of excess protein in urine) and retinopathy (lossof the vision related to diabetes).
The associations between the treatments to reduce the PA and the results were not significantly different, regardless of the class of drugs used, except for strokes and heart failure.
Although the proportional associations of the treatment to reduce blood pressure in most of the results studied were a decrease below a level of the 140 mm Hg systolic PA, the data indicates that the additional reduction below 130 mm HG is associatedWith a lower risk of stroke, retinopathy and albuminuria, which can generate net benefits for many people at high risk of those results.